

EP 164: Groundbreaking advances in MMR-deficient rectal cancer, liquid biopsies, and precision oncology with Dr. Luis Diaz
Dec 5, 2024
Dr. Luis Diaz, Co-founder and CEO of DeepMind, discusses groundbreaking advances in immunotherapy for MMR-deficient rectal cancer, highlighting a 100% tumor regression rate without chemotherapy or surgery. He delves into the marriage between cancer genomics and immunotherapy, explores the implications of FDA approvals for checkpoint inhibitors, and unveils the game-changing potential of liquid biopsies for non-invasive cancer detection. Diaz also shares insights on improving early detection using machine learning, with transformative applications beyond oncology.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Intro
00:00 • 2min
Advances in MMR-Deficient Rectal Cancer Treatment
02:03 • 19min
Advancements in Cancer Prevention Strategies
21:32 • 2min
Advancements in Cancer Detection
23:12 • 18min
Expanding the Horizons of Liquid Biopsies and Precision Medicine
41:42 • 4min
Closing Remarks and Resources for Staying Informed in Oncology
45:34 • 2min